Biomaterials Based on Bacteria for Cancer Clinical Therapy
Source abstract
Abstract
Cancer remains a major global health burden, necessitating innovative therapies. Bacterial therapy has reemerged as a transformative strategy, particularly for the potential to overcome resistance to conventional treatments. Bacteria could selectively colonize the hypoxic, acidic, and immunosuppressive tumor microenvironment. Besides, synthetic biology has enabled these bacteria to be engineered into precise living therapeutics, capable of localized drug delivery, targeted immune modulation, and remodeling of the tumor microenvironment. This review systematically explores the mechanisms by which engineered bacteria exert antitumor effects, including direct oncolysis, immunogenic cell death, and reversal of immunosuppression. Furthermore, the synergistic potential of bacterial therapy with standard therapies is discussed. Bacteria can sensitize tumors to chemotherapy through prodrug activation or reverse microbiota-mediated chemoresistance. In radiotherapy, bacteria could act as radiosensitizers and radioprotectors while amplifying abscopal effects. Combined with immunotherapy, they effectively convert immunologically “cold” tumors into “hot” ones, enhancing the application of immune checkpoint inhibitors. The role of the gut microbiota in shaping systemic antitumor immunity is also discussed. Finally, the article critically assesses the clinical translation landscape, examining representative strains in development, addressing safety and manufacturing challenges, and highlighting future directions. This review aims to provide a foundational perspective for developing safer and more effective bacterially mediated anticancer strategies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Biopolymer Synthesis and Applications · Probiotics and Fermented Foods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Shandong Traditional Chinese Medicine University, Department of Radiation Oncology, The First Affiliated Hospital of Shandong First Medical University
Department of Thoracic Surgery, Jinan Central Hospital, Jinan 250013, People’s Republic of China.
Jinan Third People’s Hospital
School of Preventive Medicine Sciences, Shandong First Medical University, Jinan 250117, People’s Republic of China.
Funding
National Natural Science Foundation of China · Natural Science Foundation of Shandong Province
References (100+)
Show source-provided references
1. Zheng R, Wang S, Zhang S, Zeng H, Chen R, Sun K, Li L, Bray F, Wei W. Global, regional, and national lifetime probabilities of developing cancer in 2020. Sci Bull. 2023;68(21):2620–2628.10.1016/j.scib.2023.09.041 ↗
2. Krishnan SR, Bebawy M. Circulating biosignatures in multiple myeloma and their role in multidrug resistance. Mol Cancer. 2023;22(1):79.10.1186/s12943-022-01683-w ↗
3. Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E. Immunotherapies in rare cancers. Mol Cancer. 2023;22(1):23.10.1186/s12943-023-01720-2 ↗
4. 10.1016/j.apsb.2022.02.02510.1016/j.apsb.2022.02.025 ↗
5. Zhao N, Song Y, Xie X, Zhu Z, Duan C, Nong C, Wang H, Bao R. Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development. Signal Transduct Target Ther. 2023;8(1):112.10.1038/s41392-023-01375-x ↗
6. 10.1289/ehp.080043910.1289/ehp.0800439 ↗
7. Huang X, Pan J, Xu F, Shao B, Wang Y, Guo X, Zhou S. Bacteria-based cancer immunotherapy. Adv Sci. 2021;8(7):2003572.10.1002/advs.202003572 ↗
8. Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.10.1186/s13045-022-01335-y ↗
9. 10.1073/pnas.203659810010.1073/pnas.2036598100 ↗
10. Kimura T, Isaka Y, Yoshimori T. Autophagy and kidney inflammation. Autophagy. 2017;13(1):997–1003.10.1080/15548627.2017.1309485 ↗
11. Liu H, Zhang H, Han Y, Hu Y, Geng Z, Su J. Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy. Theranostics. 2022;12(15):6576–6594.10.7150/thno.78034 ↗
12. Yang M, Meng Y, Li J, Bai L, Cheng Y, Liu Y, Cao M, Yang X, Wang Y, Liu Y. Nanofabricated bacterial cell walls with intrinsic peroxidase-mimicking and sonodynamic activities for cancer combination treatment. Adv Sci. 2025;12(30): Article e2505310.10.1002/advs.202505310 ↗
13. Lin H, Wang Y, Wang P, Long F, Wang T. Mutual regulation between n6-methyladenosinem(6a) modification and circular rnas in cancer: Impacts on therapeutic resistance. Mol Cancer. 2022;21(1):148.10.1186/s12943-022-01620-x ↗
14. Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: Anti-pd-(L)1-based strategy. J Exp Clin Cancer Res. 2022;41(1):56.10.1186/s13046-022-02273-w ↗
15. He SJ, Yang F, Zuo JP, Lin ZM. Fine-tuning immunity against cancer: The emergence of engineered commensal microbiota. Sci Bull. 2023;68(12):1235–1237.10.1016/j.scib.2023.05.024 ↗
16. He X, Xiong LH, Zhao Z, Wang Z, Luo L, Lam JWY, Kwok RTK, Tang BZ. AIE-based theranostic systems for detection and killing of pathogens. Theranostics. 2019;9(11):3223–3248.10.7150/thno.31844 ↗
17. Lu ZG, Shen J, Yang J, Wang J-W, Zhao R-C, Zhang T-L, Guo J, Zhang X. Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct Target Ther. 2023;8(1):39.10.1038/s41392-022-01298-z ↗
18. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135.10.1038/s41392-022-00974-4 ↗
19. Cho JY, Liu R, Macbeth JC, Hsiao A. The interface of Vibrio cholerae and the gut microbiome. Gut Microbes. 2021;13(1):1937015.10.1080/19490976.2021.1937015 ↗
20. Wang X, Shan M, Zhang S, Chen X, Liu W, Chen J, Liu X. Stimuli-responsive antibacterial materials: Molecular structures, design principles, and biomedical applications. Adv Sci. 2022;9(13): Article e2104843.10.1002/advs.202104843 ↗
21. 10.1016/j.apsb.2018.01.00710.1016/j.apsb.2018.01.007 ↗
22. Inigo JR, Chandra D. The mitochondrial unfolded protein response (UPRmt): Shielding against toxicity to mitochondria in cancer. J Hematol Oncol. 2022;15(1):98.10.1186/s13045-022-01317-0 ↗
23. Stejskal P, Goodarzi H, Srovnal J, Hajdúch M, van 't Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: Biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22(1):15.10.1186/s12943-022-01710-w ↗
24. Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018;17(1):7.10.1186/s12943-018-0759-3 ↗
25. Aguirre AM, Sorg JA. Gut associated metabolites and their roles in clostridioides difficile pathogenesis. Gut Microbes. 2022;14(1):2094672.10.1080/19490976.2022.2094672 ↗
26. Jiang T, Yang T, Chen Y, Miao Y, Xu Y, Jiang H, Yang M, Mao C. Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics. Theranostics. 2022;12:2833–2859.10.7150/thno.70719 ↗
27. Becerra-Bez EI, Meza-Toledo SE, Muoz-Lpez P, Magaño-Bocanegra KJ, Juárez-Hernández U, Mateos-Chávez AA, Luria-Pérez R. Recombinant attenuated Salmonella enterica as a delivery system of heterologous molecules in cancer therapy. Cancer. 2022;14(17):4224.10.3390/cancers14174224 ↗
28. 10.1038/nrc293410.1038/nrc2934 ↗
29. Wei X, Du M, Chen Z, Yuan Z. Recent advances in bacteria-based cancer treatment. Cancer. 2022;14(14):4945.10.3390/cancers14194945 ↗
30. Mohamed MM, Al-Raawi D, Sabet SF, El-Shinawi M. Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res. 2014;5(5):525–536.10.1016/j.jare.2013.06.004 ↗
31. Zhao Q, Maynard CL. Mucus, commensals, and the immune system. Gut Microbes. 2022;14(1):2041342.10.1080/19490976.2022.2041342 ↗
32. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol. 2022;20(1):395.10.1186/s12951-022-01605-4 ↗
33. 10.3390/ijms1205330310.3390/ijms12053303 ↗
34. Zarrabi K, Paroya A, Wu S. Emerging therapeutic agents for genitourinary cancers. J Hematol Oncol. 2019;12(1):89.10.1186/s13045-019-0780-z ↗
35. Zhao C, Liu W, Zhu M, Wu C, Zhu Y. Bioceramic-based scaffolds with antibacterial function for bone tissue engineering: A review. Bioact Mater. 2022;18:383–398.
36. Wang Y, Zhang M, Yan Z, Ji S, Xiao S, Gao J. Metal nanoparticle hybrid hydrogels: The state-of-the-art of combining hard and soft materials to promote wound healing. Theranostics. 2024;14(4):1534–1560.10.7150/thno.91829 ↗
37. Zhang Y, Zhou L, Xia J, Dong C, Luo X. Human microbiome and its medical applications. Front Mol Biosci. 2021;8: Article 703585.10.3389/fmolb.2021.703585 ↗
38. Sahli C, Moya SE, Lomas JS, Gravier-Pelletier C, Briandet R, Hémadi M. Recent advances in nanotechnology for eradicating bacterial biofilm. Theranostics. 2022;12(5):2383–2405.10.7150/thno.67296 ↗
39. Vogel U, Beerens K, Desmet T. Nucleotide sugar dehydratases: Structure, mechanism, substrate specificity, and application potential. J Biol Chem. 2022;298(4): Article 101809.10.1016/j.jbc.2022.101809 ↗
40. Das TK, Ganesh BP. Interlink between the gut microbiota and inflammation in the context of oxidative stress in Alzheimer’s disease progression. Gut Microbes. 2023;15(1):2206504.10.1080/19490976.2023.2206504 ↗
41. Apostolos AJ, Chordia MD, Kolli SH, Dalesandro BE, Rutkowski MR, Pires MM. Real-time non-invasive fluorescence imaging of gut commensal bacteria to detect dynamic changes in the microbiome of live mice. Cell Chem Biol. 2022;S2451-9456(22):1721–1728.10.1016/j.chembiol.2022.11.010 ↗
42. Lou X, Chen Z, He Z, Sun M, Sun J. Bacteria-mediated synergistic cancer therapy: Small microbiome has a big hope. Nanomicro Lett. 2021;13(1):37.
43. Zhuang H, Zhang Y, Fu Y, Ke D, Chen Q, Shao S, Xue P, Chen Y, Zeng X, Yan S. Microwave-activated bacterial biorobot for multimodal cancer therapy. Adv Sci. 2025;(41): Article e04603.10.1002/advs.202504603 ↗
44. Wang L, Wu Q, Lyu Q, Lu D, Guo L, Zhong C, Wang M, Liu C, An B, Xu H, et al. Genetically designed living bacteria with melanogenesis for tumor-specific pigmentation and therapeutic intervention. Adv Sci. 2024;11(31): Article e2402709.10.1002/advs.202402709 ↗
45. 10.1038/s41392-023-01703-110.1038/s41392-023-01703-1 ↗
46. Guo Y, Jing D, Liu S, Yuan Q. Construction of intelligent moving micro/nanomotors and their applications in biosensing and disease treatment. Theranostics. 2023;13(9):2993–3020.10.7150/thno.81845 ↗
47. Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, Li Q. Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15(1):47.10.1186/s13045-022-01273-9 ↗
48. 10.1016/j.apsb.2022.03.01110.1016/j.apsb.2022.03.011 ↗
49. 10.1016/j.cell.2024.02.02210.1016/j.cell.2024.02.022 ↗
50. Gieg R, Eriani G. The tRNA identity landscape for aminoacylation and beyond. Nucleic Acids Res. 2023;51(4):1528–1570.10.1093/nar/gkad007 ↗
51. Grode L, Kaufmann SH, Hess J. Contribution of Fusobacterium nucleatum class i-dependent immune mechanisms induced by attenuated recombinant salmonella typhimurium secreting superoxide dismutase to protection against murine listeriosis. Vaccine. 2001;19(23-24):3269–3272.10.1016/S0264-410X(01)00022-6 ↗
52. Miao Y, Yang T, Yang S, Yang M, Mao C. Protein nanoparticles directed cancer imaging and therapy. Nano Converg. 2022;9(1):2.10.1186/s40580-021-00293-4 ↗
53. Lcuyer T, Teston E, Ramirez-Garcia G, Maldiney T, Viana B, Seguin J, Mignet N, Scherman D, Richard C, et al. Chemically engineered persistent luminescence nanoprobes for bioimaging. Theranostics. 2016;6(13):2488–2524.10.7150/thno.16589 ↗
54. Sun R, Dai J, Ling M, Yu L, Yu Z, Tang L. Delivery of triptolide: A combination of traditional chinese medicine and nanomedicine. J Nanobiotechnol. 2022;20(1):194.10.1186/s12951-022-01389-7 ↗
55. 10.1186/s13045-022-01292-610.1186/s13045-022-01292-6 ↗
56. Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X, Yang H. Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol. 2022;15(1):26.10.1186/s13045-022-01249-9 ↗
57. 10.1038/s41423-021-00781-x10.1038/s41423-021-00781-x ↗
58. 10.1016/j.bioactmat.2022.03.04310.1016/j.bioactmat.2022.03.043 ↗
59. Athari SS. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther. 2019;4:45.10.1038/s41392-019-0079-0 ↗
60. Wu YH, Chen RJ, Chiu HW, Yang L-X, Wang Y-L, Chen Y-Y, Yeh Y-L, Liao M-Y, Wang Y-J. Nanoparticles augment the therapeutic window of rt and immunotherapy for treating cancers: Pivotal role of autophagy. Theranostics. 2023;13(1):40–58.10.7150/thno.77233 ↗
61. 10.1016/j.apsb.2021.12.02110.1016/j.apsb.2021.12.021 ↗
62. Jang MJ, Kim JE, Chung YH, Lee WB, Shin YK, Lee JS, Kim D, Park Y-M. Dendritic cells stimulated with outer membrane protein a (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity. Vaccine. 2011;29(13):2400–2410.10.1016/j.vaccine.2011.01.036 ↗
63. Zhang Y, Lei Y, Ou Q, Chen M, Tian S, Tang J, Li R, Liang Q, Chen Z, Wang C. Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway. BMC Biol. 2024;22(1):88.10.1186/s12915-024-01876-3 ↗
64. Tang Y, Yu Z, Lu X, Fan Q, Huang W. Overcoming vascular barriers to improve the theranostic outcomes of nanomedicines. Adv Sci. 2022;9(13): Article e2103148.10.1002/advs.202103148 ↗
65. 10.1016/j.jconrel.2021.05.00610.1016/j.jconrel.2021.05.006 ↗
66. Huayamares SG, Lian L, Rab R, Hou Y, Radmand A, Kim H, Zenhausern R, Achyut BR, Ross MG, Lokugamage MP, et al. Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses. Nat Commun. 2025;16(1):3490.10.1038/s41467-025-58548-1 ↗
67. 10.1016/j.addr.2017.09.01210.1016/j.addr.2017.09.012 ↗
68. Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer. 2022;10(5): Article e004167.10.1136/jitc-2021-004167 ↗
69. 10.3389/fchem.2021.61735310.3389/fchem.2021.617353 ↗
70. Leong SW, Tan SC, Norhayati MN, Monif M, Lee SY. Effectiveness of bioinks and the clinical value of 3D bioprinted glioblastoma models: A systematic review. Cancer. 2022;14(9):2149.10.3390/cancers14092149 ↗
71. Deng S, Gu J, Jiang Z, Cao Y, Mao F, Xue Y, Wang J, Dai K, Qin L, Liu K, et al. Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer. J Nanobiotechnology. 2022;20(1):415.10.1186/s12951-022-01613-4 ↗
72. Xue C, Chu Q, Zheng Q, Jiang S, Bao Z, Su Y, Lu J, Li L. Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther. 2022;7(1):142.10.1038/s41392-022-01003-0 ↗
73. Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.10.1186/s13045-022-01242-2 ↗
74. Lv W, Liu Y, Li S, Lv L, Lu H, Xin H. Advances of nano drug delivery system for the theranostics of ischemic stroke. J Nanobiotechnology. 2022;20:248.10.1186/s12951-022-01450-5 ↗
75. Oh JM, Kim H. The effect of oral bacterial infection on DNA damage response in host cells. Am J Cancer Res. 2023;13:3157–3168.
76. 10.1016/j.scib.2024.06.01610.1016/j.scib.2024.06.016 ↗
77. 10.1126/sciadv.adt034110.1126/sciadv.adt0341 ↗
78. Pappas-Gogos G, Tepelenis K, Fousekis F, Katsanos K, Pitiakoudis M, Vlachos K. The implication of gastric microbiome in the treatment of gastric cancer. Cancer. 2022;14(8):2039.10.3390/cancers14082039 ↗
79. 10.1016/j.trecan.2019.08.00210.1016/j.trecan.2019.08.002 ↗
80. Chen Z, Kankala RK, Yang Z, Li W, Xie S, Li H, Chen A-Z, Zou L. Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics. 2022;12(8):3719–3746.10.7150/thno.72594 ↗
81. Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022;10(4): Article e004462.10.1136/jitc-2021-004462 ↗
82. Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian rhythms and cancers: The intrinsic links and therapeutic potentials. J Hematol Oncol. 2022;15(1):21.10.1186/s13045-022-01238-y ↗
83. 10.1038/s41392-023-01332-810.1038/s41392-023-01332-8 ↗
84. Li L, Yang Z, Yi Y, Song Y, Zhang W. Gut microbiota and radiation-induced injury: Mechanistic insights and microbial therapies. Gut Microbes. 2025;17(1):2528429.10.1080/19490976.2025.2528429 ↗
85. Wu X, Zhang J, Deng Z, Sun X, Zhang Y, Zhang C, Wang J, Yu X, Yang G. Bacteria-based biohybrids for remodeling adenosine-mediated immunosuppression to boost radiotherapy-triggered antitumor immune response. Biomaterials. 2025;316: Article 123000.10.1016/j.biomaterials.2024.123000 ↗
86. Tegegne BA, Kebede B. Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature. Heliyon. 2022;8: Article e09725.10.1016/j.heliyon.2022.e09725 ↗
87. Seeber LM, Horre N, Vooijs MA, Heintz APM, van der Wall E, Verheijen RHM, van Diest PJ. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol. 2011;78(3):173–184.10.1016/j.critrevonc.2010.05.003 ↗
88. Chen W, Wang S, Wu Y, Shen X, Guo Z, Li Q, Xing D. Immunogenic cell death: A link between gut microbiota and anticancer effects. Microb Pathog. 2020;141: Article 103983.10.1016/j.micpath.2020.103983 ↗
89. 10.3389/fbioe.2022.102002010.3389/fbioe.2022.1020020 ↗
90. 10.1021/acsnano.8b0223510.1021/acsnano.8b02235 ↗
91. Zhang P, Hu C, Ran W, Meng J, Yin Q, Li Y. Recent progress in light-triggered nanotheranostics for cancer treatment. Theranostics. 2016;6(7):948–968.10.7150/thno.15217 ↗
92. Prez Jorge G, Gontijo MTP, Brocchi M. Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment. Front Cell Infect Microbiol. 2023;13:1293351.10.3389/fcimb.2023.1293351 ↗
93. Xiang S, Zhan H, Zhan J, Li X, Lin X, Sun W. Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced t cell-mediated tumor immunotherapy. Int J Pharm X. 2025;10: Article 100400.
94. Lai X, Lu T, Zhang F, Khan A, Zhao Y, Li X, Xiang S, Lin K. Lysosome-targeted theranostics: Integration of real-time fluorescence imaging and controlled drug delivery via Zn(II)-Schiff Base complexes. J Inorg Biochem. 2025;272: Article 113015.10.1016/j.jinorgbio.2025.113015 ↗
95. Yang J, Dai D, Zhang X, Teng L, Ma L, Yang Y-W. Multifunctional metal-organic framework (MOF)-based nanoplatforms for cancer therapy: From single to combination therapy. Theranostics. 2023;13(1):295–323.10.7150/thno.80687 ↗
96. Tafesh-Edwards G, Eleftherianos I. The role of drosophila microbiota in gut homeostasis and immunity. Gut Microbes. 2023;15(1):2208503.10.1080/19490976.2023.2208503 ↗
97. Ding M, Zhang Y, Li J, Pu K. Bioenzyme-based nanomedicines for enhanced cancer therapy. Nano Converg. 2022;9(1):7.10.1186/s40580-022-00297-8 ↗
98. Galeano Nio JL, Ponath F, Ajisafe VA, Becker CR, Kempchinsky AG, Zepeda-Rivera MA, Gomez JA, Wu H, Terrazas JG, Bouzek H, et al. Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer Cell. 2025;44(1):166–186.e16.10.1016/j.ccell.2025.09.010 ↗
99. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-Oncology. 2018;20(12):1566–1572.10.1093/neuonc/noy072 ↗
100. Chen J, Tan Q, Yang Z, Jin Y. Engineered extracellular vesicles: Potentials in cancer combination therapy. J Nanobiotechnology. 2022;20(1):132.10.1186/s12951-022-01330-y ↗